What topics does this cannabis study cover?

This study covers research on: Mental Health.

Where was this research published?

Published in Clinical therapeutics on July 11, 2026.

What doctors can—and cannot—say about medical cannabis

Q: What did this research study find?

The *Controlled Substances Act* does not prohibit healthcare providers from **discussing cannabis with patients** as a possible medical or therapeutic option, despite its federal classification.

Why Healthcare Providers are Well Positioned to Talk to Patients About Medical Marijuana.

Clinical therapeutics • July 11, 2026 • Highly Relevant

🤖

AI Summary

Healthcare providers are well positioned to discuss medical marijuana and adult-use cannabis with patients, but both groups may be hesitant because of concerns about the drug’s medical uses and legal status. This commentary explains that providers can discuss the potential risks and benefits of cannabis as part of treatment conversations, even though marijuana remains federally illegal under Schedule I of the Controlled Substances Act.

The paper’s practical message is that federal law does not prohibit clinicians from discussing cannabis with patients or recommending it as a medical or therapeutic option. Because state laws and regulations vary and continue to change, healthcare organizations and providers should seek legal advice and create clear policies for addressing patients who may benefit from cannabis. The abstract reports no quantitative results; its contribution is legal and clinical guidance rather than an efficacy finding.

💡 Key Findings

The Controlled Substances Act does not prohibit healthcare providers from discussing cannabis with patients as a possible medical or therapeutic option, despite its federal classification.

High

85%

Providers can discuss the risks and benefits of medical marijuana and may recommend it, while recognizing that state laws and institutional policies may impose additional restrictions.

High

80%

Because cannabis laws are changing, healthcare organizations should develop clear procedures and consult legal advisors when creating guidance for clinicians and patients.

High

80%

📄 Original Abstract

Healthcare providers are well-positioned to talk to patients about medical and recreational, a.k.a., adult, marijuana, a.k.a., cannabis. However, providers and patients alike experience concerns about discussing the known medical and therapeutic uses of marijuana. This commentary provides a legal overview on how healthcare providers can navigate federal and state legal laws and restrictions to discuss the risks and benefits of marijuana and recommend it to their patients. While marijuana is still federally illegal under Schedule I of the Controlled Substances Act (CSA), providers may not realize that the CSA does not prohibit them from discussing marijuana with their patients as an option for medical and therapeutic treatment. Given the rapidly evolving nature of federal and state laws and regulations, providers are encouraged to consult legal and other advisors to develop policies and procedures that enable them to address the needs of patients who may benefit from marijuana use.